Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311931 | 0.93 | OPRM1 (0.42) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2310329 | 0.93 | OPRM1 (0.57) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2310823 | 0.92 | OPRM1 (0.49) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2309188 | 0.88 | OPRM1 (0.51) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2381415 | 0.88 | NPC1L1 (0.45) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2310630 | 0.87 | ALDH1A1 (0.45) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2307819 | 0.87 | OPRM1 (0.51) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2306085 | 0.87 | OPRM1 (0.51) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2381146 | 0.86 | CHRM2 (0.45) | OPRM1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2309697 | 0.85 | OPRM1 (0.60) | OPRM1HRH3HTTOPRD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | OPRM1 431/4885CHRM2 115/4885CHRM4 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.